We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+0.8%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.76B
AUM Growth
-$301M
Cap. Flow
-$879M
Cap. Flow %
-18.47%
Top 10 Hldgs %
31.51%
Holding
169
New
40
Increased
23
Reduced
18
Closed
45

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$128M
2
BSX icon
Boston Scientific
BSX
+$108M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$89.6M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$76M
5
TOI icon
The Oncology Institute
TOI
+$53.3M

Top Sells

Rank Stock Value
1
NKTX icon
Nkarta
NKTX
+$87.3M
2
SWTX
SpringWorks Therapeutics
SWTX
+$69.3M
3
OSH
Oak Street Health, Inc.
OSH
+$58.2M
4
DFPHU
DFP Healthcare Acquisitions Corp. Unit
DFPHU
+$56.1M
5
DFHTU
Deerfield Healthcare Technology Acquisitions Corp. Unit
DFHTU
+$50.4M

Sector Composition

Rank Sector Weight
1 Healthcare 70.89%
2 Consumer Discretionary 0.23%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONCR
26
DELISTED
Oncorus, Inc.
ONCR
$43.8M 0.92%
3,148,977
+300,000
+11% +$6.21M
LUNG icon
27
Pulmonx
LUNG
$59.1M
$42.9M 0.9%
937,032
+473,521
+102% +$27.2M
RYTM icon
28
Rhythm Pharmaceuticals
RYTM
$7.31B
$42.3M 0.89%
1,989,625
-731,578
-27% -$21.2M
RETA
29
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$41.9M 0.88%
420,000
+100,000
+31% +$11.7M
SWTX
30
DELISTED
SpringWorks Therapeutics
SWTX
$41.1M 0.86%
558,574
-884,396
-61% -$69.3M
CNST
31
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$40M 0.84%
1,708,957
+250,000
+17% +$7.57M
INZY
32
DELISTED
Inozyme Pharma
INZY
$38.9M 0.82%
1,964,000
+813,701
+71% +$18M
BDSI
33
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$37.3M 0.78%
9,530,000
– –
PBYI icon
34
Puma Biotechnology
PBYI
$434M
$36.6M 0.77%
3,769,795
-189,946
-5% -$2.12M
ISEE
35
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$35.6M 0.75%
5,767,409
– –
APR
36
DELISTED
Apria, Inc. Common Stock
APR
$33.5M 0.7%
+1,200,000
New +$27.1M
PTGX icon
37
Protagonist Therapeutics
PTGX
$9.06B
$32.6M 0.69%
1,258,790
-121,181
-9% -$3.07M
NUVB icon
38
Nuvation Bio
NUVB
$2.02B
$31.4M 0.66%
+3,000,000
New +$33.5M
HRC
39
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$30.9M 0.65%
+279,870
New +$29.2M
XLRN
40
DELISTED
Acceleron Pharma
XLRN
$29.8M 0.63%
219,500
-202,119
-48% -$26.1M
XERS icon
41
Xeris Biopharma Holdings
XERS
$1.52B
$29.6M 0.62%
+6,553,398
New +$35.3M
CALC icon
42
CalciMedica
CALC
$11.6M
$29.3M 0.62%
377,265
– –
PHVS icon
43
Pharvaris
PHVS
$2.44B
$28.9M 0.61%
+1,032,757
New +$32.5M
ITMR
44
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$28.6M 0.6%
1,193,803
+400,000
+50% +$9.51M
TIL icon
45
Instil Bio
TIL
$50.3M
$28M 0.59%
+55,787
New +$28.6M
SHC icon
46
Sotera Health
SHC
$5.06B
$27.7M 0.58%
1,111,000
– –
FOLD
47
DELISTED
Amicus Therapeutics
FOLD
$26.7M 0.56%
+2,698,497
New +$41.8M
BCRX icon
48
BioCryst Pharmaceuticals
BCRX
$2.36B
$26.5M 0.56%
2,605,380
-3,230,430
-55% -$33.3M
KALV
49
DELISTED
KalVista Pharmaceuticals
KALV
$26.2M 0.55%
+1,020,005
New +$26.8M
PROF
50
Profound Medical
PROF
$249M
$26.1M 0.55%
1,297,797
+602,797
+87% +$14.5M
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q1 2021 Portfolio in Review

As of Q1 2021, Deerfield Management held 169 positions worth $4.76B, down 6% from $5.06B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Deerfield Management withdrew a net $879M in Q1 2021, closing 45 positions and reducing 18 holdings. Its most notable exit was Nkarta, an estimated $87.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 70% a quarter earlier, followed by Consumer Discretionary and Industrials.

Against the trend, Deerfield Management opened a new position in Edgewise Therapeutics worth $128M.

  • Deerfield Management's largest Q1 2021 buy was Edgewise Therapeutics: 3,933,137 shares worth $128M.
  • Deerfield Management added most to The Oncology Institute in Q1 2021, an estimated $53.3M increase.
  • Deerfield Management's biggest Q1 2021 reduction was SpringWorks Therapeutics, cutting an estimated $69.3M.
  • Deerfield Management fully exited Nkarta in Q1 2021, selling an estimated $87.3M.
  • Deerfield Management's ten largest holdings make up 32% of its $4.76B portfolio in Q1 2021.
  • Deerfield Management opened 40 new positions and closed 45 in Q1 2021.
  • Deerfield Management's portfolio value fell 6% quarter-over-quarter to $4.76B.

Based on Deerfield Management's 13F filing for Q1 2021, filed 17 May 2021.